Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

SIMPLE SUMMARY: An early assessment of response to treatment is crucial to informing appropriate therapeutic management. Using a plasma-only strategy, we measured changes in circulating tumor DNA (ctDNA) levels after one or two cycles of chemotherapy in 92 patients with advanced non-small-cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaung, Stephanie J., Woestmann, Corinna, Ju, Christine, Ma, Xiaoju Max, Gattam, Sandeep, Zhou, Yiyong, Xi, Liu, Pal, Subrata, Balasubramanyam, Aarthi, Tikoo, Nalin, Heussel, Claus Peter, Thomas, Michael, Kriegsmann, Mark, Meister, Michael, Schneider, Marc A., Herth, Felix J., Wehnl, Birgit, Diehn, Maximilian, Alizadeh, Ash A., Palma, John F., Muley, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139958/
https://www.ncbi.nlm.nih.gov/pubmed/35626082
http://dx.doi.org/10.3390/cancers14102479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139958/
https://www.ncbi.nlm.nih.gov/pubmed/35626082
http://dx.doi.org/10.3390/cancers14102479

Ejemplares similares